Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis

Zi-Han Zhang; Zi-Han Zhang; Zi-Han Zhang; Si-Nan Hou; Si-Nan Hou; Si-Nan Hou; Jia-Ze Yu; Jia-Ze Yu; Jia-Ze Yu; Wen Zhang; Wen Zhang; Wen Zhang; Jing-Qin Ma; Jing-Qin Ma; Jing-Qin Ma; Min-Jie Yang; Min-Jie Yang; Min-Jie Yang; Qing-Xin Liu; Qing-Xin Liu; Qing-Xin Liu; Ling-Xiao Liu; Ling-Xiao Liu; Ling-Xiao Liu; Jian-Jun Luo; Jian-Jun Luo; Jian-Jun Luo; Xu-Dong Qu; Xu-Dong Qu; Xu-Dong Qu; Zhi-Ping Yan; Zhi-Ping Yan; Zhi-Ping Yan

doi:10.3389/fonc.2022.1086095

Frontiers in Oncology (Jan 2023)

Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis

Zi-Han Zhang,
Zi-Han Zhang,
Zi-Han Zhang,
Si-Nan Hou,
Si-Nan Hou,
Si-Nan Hou,
Jia-Ze Yu,
Jia-Ze Yu,
Jia-Ze Yu,
Wen Zhang,
Wen Zhang,
Wen Zhang,
Jing-Qin Ma,
Jing-Qin Ma,
Jing-Qin Ma,
Min-Jie Yang,
Min-Jie Yang,
Min-Jie Yang,
Qing-Xin Liu,
Qing-Xin Liu,
Qing-Xin Liu,
Ling-Xiao Liu,
Ling-Xiao Liu,
Ling-Xiao Liu,
Jian-Jun Luo,
Jian-Jun Luo,
Jian-Jun Luo,
Xu-Dong Qu,
Xu-Dong Qu,
Xu-Dong Qu,
Zhi-Ping Yan,
Zhi-Ping Yan,
Zhi-Ping Yan

Affiliations

Zi-Han Zhang: Department of Interveintional Radiology, Zhongshan hospital, Fudan, University, Shanghai, China
Zi-Han Zhang: Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China
Zi-Han Zhang: National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
Si-Nan Hou: Department of Interveintional Radiology, Zhongshan hospital, Fudan, University, Shanghai, China
Si-Nan Hou: Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China
Si-Nan Hou: National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
Jia-Ze Yu: Department of Interveintional Radiology, Zhongshan hospital, Fudan, University, Shanghai, China
Jia-Ze Yu: Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China
Jia-Ze Yu: National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
Wen Zhang: Department of Interveintional Radiology, Zhongshan hospital, Fudan, University, Shanghai, China
Wen Zhang: Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China
Wen Zhang: National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
Jing-Qin Ma: Department of Interveintional Radiology, Zhongshan hospital, Fudan, University, Shanghai, China
Jing-Qin Ma: Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China
Jing-Qin Ma: National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
Min-Jie Yang: Department of Interveintional Radiology, Zhongshan hospital, Fudan, University, Shanghai, China
Min-Jie Yang: Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China
Min-Jie Yang: National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
Qing-Xin Liu: Department of Interveintional Radiology, Zhongshan hospital, Fudan, University, Shanghai, China
Qing-Xin Liu: Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China
Qing-Xin Liu: National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
Ling-Xiao Liu: Department of Interveintional Radiology, Zhongshan hospital, Fudan, University, Shanghai, China
Ling-Xiao Liu: Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China
Ling-Xiao Liu: National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
Jian-Jun Luo: Department of Interveintional Radiology, Zhongshan hospital, Fudan, University, Shanghai, China
Jian-Jun Luo: Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China
Jian-Jun Luo: National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
Xu-Dong Qu: Department of Interveintional Radiology, Zhongshan hospital, Fudan, University, Shanghai, China
Xu-Dong Qu: Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China
Xu-Dong Qu: National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
Zhi-Ping Yan: Department of Interveintional Radiology, Zhongshan hospital, Fudan, University, Shanghai, China
Zhi-Ping Yan: Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China
Zhi-Ping Yan: National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China

DOI: https://doi.org/10.3389/fonc.2022.1086095
Journal volume & issue: Vol. 12

Abstract

Read online

ObjectiveTo evaluate the safety and efficacy of interventional therapy (iodine-125[125I] seed strand and portal vein stent [PVS] implantation plus transarterial chemoembolization [TACE]) combined with systemic therapy (lenvatinib plus anti-PD-1 antibody) as first-line treatment for hepatocellular carcinoma (HCC) patients with Vp4 portal vein tumor thrombus (PVTT).Patients and methodsFrom December 2018 to October 2021, 87 HCC patients with Vp4 PVTT were included in this single-center retrospective study. Forty-seven patients underwent interventional therapy combined with lenvatinib and anti-PD-1 antibody (group A), while 40 cases underwent interventional therapy combined with lenvatinib only (group B). Overall response rate (ORR), stent occlusion rates (SOR), median overall survival (OS), median progression-free survival (PFS) and median stent patency time (SPT) were compared between the 2 groups.ResultsThe mean intended dose (r = 10 mm; z = 0; 240 days) was 64.9 ± 1.0 Gy and 64.5 ± 1.1 Gy in group A and B, respectively (p = 0.133). ORR and SOR were significantly different between group A and B (ORR, 55.3% vs 17.5%, p < 0.001; SOR, 12.8% vs 35.0%, p = 0.014). In the propensity-score matching (PSM) cohort, the median OS, median PFS and median SPT were significantly longer in group A compared with group B (32 PSM pairs; OS, 17.7 ± 1.7 vs 12.0 ± 0.8 months, p = 0.010; PFS, 17.0 ± 4.3 vs 8.0 ± 0.7 months, p < 0.001; SPT, not-reached vs 12.5 ± 1.1 months, p = 0.028).ConclusionThis interventional therapy combined with lenvatinib and anti-PD-1 antibody is safe and effective for HCC patients with Vp4 PVTT.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords